Pemigatinib for the treatment of myeloid/lymphoid neoplasms with <i>FGFR1</i> rearrangement.

Freyer, Craig W; Hughes, Mitchell E; Carulli, Alison; Bagg, Adam; Hexner, Elizabeth

Pemigatinib for the treatment of myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Freyer, Craig W; Hughes, Mitchell E; Carulli, Alison; Bagg, Adam; Hexner, Elizabeth.

Freyer CW; Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Hughes ME; Department of Medicine, Division of Hematology/Oncology, Perelman School of Medicine and the Hospital of the University of Pennsylvania, University of Pennsylvania, Philadelphia, PA, USA.
Carulli A; Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Bagg A; Lymphoma Program, Hematology/Oncology Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Hexner E; Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.

Expert Rev Anticancer Ther ; 23(4): 351-359, 2023 04.

Article en En | MEDLINE | ID: mdl-36927350

Asunto(s)

Linfoma; Trastornos Mieloproliferativos; Humanos; Trastornos Mieloproliferativos/tratamiento farmacológico; Trastornos Mieloproliferativos/genética; Morfolinas; Pirimidinas/farmacología; Translocación Genética; Receptor Tipo 1 de Factor de Crecimiento de Fibroblastos/genética

Palabras clave

FGFR1 rearrangement; Fibroblast growth factor receptor; eosinophilia; myeloid/lymphoid neoplasm; myeloproliferative neoplasm; pemigatinib

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfoma / Trastornos Mieloproliferativos Tipo de estudio: Prognostic_studies / Qualitative_research Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google